# US 2020/0406230 A1 · A protein-binding product, a device containing said protein-binding product and a method for extracorporeal reduction of the level of protein in blood plasma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0406230 A1
- Document ID: US20200406230A1
- Status: Published application
- Kind: A1
- Application number: 16/978,906
- Filed: 2019-03-08
- Published: 2020-12-31
- Earliest claimed: 2018-03-08
- Assignees: Glycorex Transplantation AB
- Applicants: Glycorex Transplantation AB
- Inventors: Kurt NILSSON
- Web page: https://patentgrep.com/patent/US20200406230A1

## CPC

- B01J 20/2803: {Sorbents comprising a binder, e.g. for forming aggregated, agglomerated or granulated products}
- A61M 1/3417: {using distinct filters for dialysis and ultra-filtration}
- A61M 1/3496: {Plasmapheresis; Leucopheresis; Lymphopheresis (A61M1/3472 takes precedence)}
- B01D 15/3809: {of the antigen-antibody type, e.g. protein A, G or L chromatography}
- B01J 20/24: Naturally occurring macromolecular compounds, e.g. humic acids or their derivatives
- B01J 20/261: {obtained by reactions only involving carbon to carbon unsaturated bonds (macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds per se C08F)}
- B01J 20/265: {modified or post-treated polymers (polymer carriers or substrates subjected to further impregnating or coating B01J20/3208)}
- B01J 20/28019: {Spherical, ellipsoidal or cylindrical}
- B01J 20/289: bonded via a spacer
- C07G 3/00: Glycosides
- C07K 1/145: {by extraction or solubilisation}
- C08B 37/0039: {Agar; Agarose, i.e. D-galactose, 3,6-anhydro-D-galactose, methylated, sulfated, e.g. from the red algae Gelidium and Gracilaria; Agaropectin; Derivatives thereof, e.g. Sepharose, i.e. crosslinked agarose}
- C08H 1/00: Macromolecular products derived from proteins (food proteins A23; glue, gelatine C09H)
- C08L 5/12: {Agar or} agar-agar {, i.e. mixture of agarose and agaropectin}; Derivatives thereof
- C08L 89/00: Compositions of proteins; Compositions of derivatives thereof
- G01N 33/548: Carbohydrates, e.g. dextran
- G01N 33/66: involving blood sugars, e.g. galactose
- G01N 2333/4724: Lectins
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)
- C07G: COMPOUNDS OF UNKNOWN CONSTITUTION (sulfonated fats, oils or waxes of undetermined constitution C07C309/62)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C08H: DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS (polysaccharides C08B; natural rubber C08C; natural resins or their derivatives C09F; bituminous materials C10)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A protein-binding product comprising one or more porous polymer beads, wherein at least one ligand is bound to the surfaces of said polymer beads via a spacer (R), and wherein said at least one ligand is Galβ1-3HexNAcβ—O—, Galβ1-4GlcNAcβ—O— and/or a derivative thereof, is disclosed as well as a device containing said protein-binding product and a method for reduction of the level of at least one galactose-binding protein and optionally at least one other protein in human blood plasma.

## Claims

### Claim 1

A protein-binding product comprising one or more porous polymer beads, wherein at least one ligand is bound to the surfaces of said polymer beads via a spacer (R), and wherein said at least one ligand is Galβ1-3HexNAcβ—O—, Galβ1-4GlcNAcβ—O— and/or a derivative thereof.

### Claim 2 (depends on 1)

The protein-binding product according to claim 1, wherein Galβ1-3HexNAcβ—O— is Galβ1-3GlcNAcβ—O— or Galβ1-3GalNAcβ—O—.

### Claim 3 (depends on 1, 2)

The protein-binding product according to claims 1 and 2, wherein said derivative of said at least one ligand has a structure in which at least the 3-OH group of Gal is substituted with one of the following groups:
a) a 3-OR2 group where the R2 group contains an alkyl group or an aromatic group,
b) a 3-OR2 group where the R2 group contains a sialyl group or a D-galactosyl group or GalNAc group,
c) a 3-NH—CO—R2 group where the R2 group contains an alkyl group or an aromatic group,
d) a 3,5-dimethoxybenzamido group.

### Claim 4

The protein-binding product according to any one of the preceding claims, wherein said at least one ligand has the ability to bind to at least one galactose-binding protein, preferably a galectin, and optionally has the ability to bind at least one other protein, preferably an antibody, more preferably a blood group A specific antibody, a blood group B specific antibody, or an autoantibody.

### Claim 5

A protein-binding product with the ability to bind galectin and with the ability to bind an autoantibody, preferably AChR (acetylcholine receptor) antibody or a MuSK (muscle-specific kinase) receptor antibody, or a toxin in human blood plasma.

### Claim 6

The protein-binding product according to any one of the preceding claims, wherein said at least one ligand has the ability to specifically bind to galectins in human blood plasma, preferably galectin-1, galectin-3, and galectin-8.

### Claim 7 (depends on 4, 6)

The protein-binding product according to any one of claims 4 and 6, wherein at least one other ligand is a blood group A and/or B antigen.

### Claim 8

The protein-binding product according to any one of the preceding claims, wherein the concentration of the ligand is in a range of 0.1-20 μmol per mL polymer, preferably 5-20 μmol per mL polymer.

### Claim 9

The protein-binding product according to any one of the preceding claims, wherein the concentration of the derivative of at least one of Galβ1-3HexNAcβ—O— or Galβ1-4GlcNAcβ—O— is in a range of 0.1-5 μmol per mL polymer.

### Claim 10

The protein-binding product according to any one of the preceding claims, wherein the spacer (R) is covalently bound to the surfaces of said porous polymer beads and is glycosidically bound to the ligand.

### Claim 11

The protein-binding product according to any one of the preceding claims, wherein the spacer is chosen from the group consisting of (CH2)nNH—, (CH2)nPhNH—, PhNH— and Ph(CH2)nNH—, wherein Ph is a phenyl group and n is an integer, preferably wherein n is one of 1, 2, 3, 4, 5 or 6.

### Claim 12

The protein-binding product according to any one of the preceding claims, wherein said porous polymer beads are agarose or cross-linked agarose beads, hydroxymethacrylate beads or other porous plastic beads.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

Use of said protein-binding product according to any one of claims 1-10 for extracorporeal reduction of the levels of at least one galactose-binding protein, preferably a galectin, more preferably galectin-1, galectin-3 and galectin-8; and optionally the levels of at least one other protein, preferably an antibody, more preferably a blood group A specific antibody, a blood group B specific antibody, an autoantibody, more preferably an AChR (acetylcholine receptor) antibody and a MuSK (muscle-specific kinase) receptor antibody, and a toxin in human blood plasma.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A device containing said protein-binding product according to any one of claims 1-12, wherein said device is a column or a tubing.

### Claim 15 (depends on 14)

A method for extracorporeal reduction of the level of at least one galactose-binding protein and optionally at least one other protein in human blood plasma, said method comprising the steps of:
a) passing the blood plasma through the device according to claim 14,
b) allowing said at least one galactose-binding protein, preferably a galectin, and optionally at least one other protein, preferably an antibody, more preferably a blood group A specific antibody, a blood group B specific antibody, an autoantibody, more preferably an AChR (acetylcholine receptor) antibody and a MuSK (muscle-specific kinase) receptor antibody; or a toxin to bind to said at least one ligand of the protein-binding product,
c) allowing at least one blood plasma volume to pass through the device after passage of one blood plasma volume through the device,
d) repeating step c) until the desired reduction of the level of said at least one galactose-binding protein and optionally at least one other protein in the blood plasma is achieved.

### Claim 16 (depends on 14)

A method for extracorporeal reduction of the level of at least one galactose-binding protein and optionally at least one other protein in human blood plasma, said method comprising the steps of:
a) passing the blood plasma through the device according to claim 14,
b) allowing said at least one galactose-binding protein, preferably a galectin, and optionally at least one other protein, preferably an antibody, more preferably a blood group A specific antibody, a blood group B specific antibody, an autoantibody, more preferably an AChR (acetylcholine receptor) antibody and a MuSK (muscle-specific kinase) receptor antibody, or a toxin to bind to said at least one ligand of the protein binding product,
c) allowing at least one blood plasma volume to pass through the device after passage of one blood plasma volume through the device,
d) repeating step c) until the desired reduction of the level of said at least one galactose-binding protein and optionally at least one other protein in the blood plasma is achieved,
e) optionally performing dialysis concomitantly with the steps above,
f) continuously returning the treated blood plasma to the patient.

### Claim 17 (depends on 3, 14, 15)

The method according to any of claims 14 and 15, wherein
Galβ1-4GlcNAcβ—O— or a derivative thereof according to claim 3 is used as ligand when the level of galectin-3 is to be reduced,
Galβ1-3GalNAcβ— or a derivative thereof in which the 3-OH group of the Gal unit has been substituted with an α2-3-linked sialyl group is used as ligand when the level of galectin-8 is to be reduced, and
Galβ1-3GlcNAcbβ—O— or a derivative thereof in which the 3-OH group of the Gal unit has been substituted with an α2-6-linked sialyl group is used as ligand when the level of galectin-1 is to be reduced.

### Claim 18 (depends on 15, 16, 17)

A method according to any of claims 15-17, wherein said method additionally comprises at least one of the following steps:
measuring the levels of galactose-binding proteins and/or at least one other protein during the treatment,
measuring the levels of galactose-binding proteins and/or at least one other protein during the treatment and
calculating the reduction of the levels of galactose-binding proteins and/or at least one other protein.
